// App-Quantinova.ai

PO0954 : Lower Cardiorenal Risk with SGLT2 Inhibitor vs. DPP4 Inhibitor in Type 2 Diabetes Patients Without Established Cardiovascular and Renal Diseases

Researchers

Presenter

  • Birkeland KreI

Principal Investigators

  • Bodegard Johan

  • Banerjee Amitava

  • Kim Dae Jung

  • Eriksson JanW

  • Thuresson Marcus

  • Okami Suguru

  • Ha Kyoung Hwa

  • Kossack Nils

  • Mamza Jil Billy

  • Zhang Ruiqi

  • Yajima Toshitaka

  • Komuro Issei

  • Kadowaki Takashi

Medical Centers

  • Oslo Universitetssykehus HF, Norway

  • AstraZeneca PLC Luton United Kingdom

  • Kings College London, London, United Kingdom

  • Ajou University School of Medicine and Graduate School of Medicine Suwon Gyeonggi-do Korea (the Republic of)

  • Uppsala Universitet Uppsala Sweden

  • Statisticon, Uppsala, Sweden

  • Wissenschaftliches Institut fur Gesundheitsökonomie und Gesundheitssystemforschung Berlin Germany

  • University of Tokyo Graduate School of Medicine School of Medicine Bunkyo-ku Tokyo Japan

  • Toranomon Byoin Minato-ku Tokyo Japan

Locations

  • Norway

  • United Kingdom

  • Sweden

  • Germany

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Myocardial infarction

  • Type 2 diabetes mellitus

  • Renal disease

  • Diabetes

  • Stroke

Biomarkers

  • Dipeptidyl peptidase IV

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Observational

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved